The United States Food and Drug Administration (US FDA) has completed a pre-approval inspection (PAI) of Edaravone oral suspension at its manufacturing facility in Somerset, New Jersey, with zero 483 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback